We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Cefazolin and Dextrose USP

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Cefazolin and Dextrose USP

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Cefazolin and Dextrose USP, for injection, has recently been approved using the Duplex drug delivery system, for the treatment of various bacterial infections. The multiple indications for this combination therapy include, but are not limited to respiratory tract infections, urinary tract infections, skin and skin structure infections, biliary tract infections, bone and joint infections, genital infections, septicemia (bloodstream infections), endocarditis (inflammatory disorder of the heart valves), and perioperative prophylaxis.

    The administration of Cefazolin and Dextrose preoperatively, intraoperatively and postoperatively to patients undergoing high risk surgeries, such as a vaginal hysterectomy or to older patients at high risk of infection due to a compromised immune system, may decrease the occurance of certain postoperative infections.

    Clinical Results

    In vitro tests have shown that the antibacterial action of Cefazolin is caused by the drug's inhibition of cell wall synthesis, therefore reducing bacterial cell growth.
    Studies have also shown that in patients hospitalized with infection, Cefazolin administered intravenously has produced the same blood serum levels seen in healthy volunteers.

    Side Effects

    Common side effects of Cefazolin and Dextrose for injection include, but are not limited to:

    Gastrointestional reactions, including:
    • Diarrhea
    • Oral candidiasis
    • Stomach cramps
    • Anorexia

    Allergic reactions, including:

    • Anaphylaxis
    • Eosinophilia
    • Itching
    • Drug fever
    • Skin rash
    • Stevens-Johnson Syndrome

    Hematologic reactions, including:

    • Neutropenia
    • Leukopenia
    • Thrombocytopenia
    • Thrombocythemia

    Some cases of Interstitial nephritis and other renal disorders have been reported rarely. In clinical trials, patients who experienced these side effects were seriously ill and were receiving multiple drug therapies. Transient hepatitis and cholestatic jaundice are also uncommon side effects associated with penicillin and cephalosporins.

    Other rare side effects include genital and anal pruritis and rare instances of phlebitis at the site of injection.

    Cefazolin and Dextrose injection is contraindicated for patients:

    • with known allergies to the cephalosporin group of antibiotics
    • with hypersensitivity to corn products
    • currently taking probenecid

    Serious or fatal hypersensitivy has been reported in patients on penicillin therapy. Anaphalactic reactions are more likely to occur in patients that have a known history of sensitivity to multiple allergans.

    Pseudomembranous colitis has also been reported and may range in severity from mild to life-threatening.

    Mechanism of Action

    Cefazolin for Injection USP and Dextrose Injection USP is a sterile, nonpyrogenic (does not induce fever), single use, packaged combination of Cefazolin Sodium USP (lyophilized) and sterile iso-osmotic dilutant in the DUPLEX sterile container. (From FDA Label) It is administered through parenteral injection or intramuscular injection.

    Additional Information

    While using Cefazoline USP and Dextrose USP diabetics may get a false-positive result when testing for sugar in their urine. Check with your doctor or a healthcare professional before changing your diet or your diabetic medication.

    Pregnant women using Cefazoline USP and Dextrose USP should know that while the drug has not been shown to have harmful effects on the fetus, no adequate or conclusive studies have been done on Cefazoline use in pregnant women. The drug is present in trace amounts in the milk of nursing mothers. Nursing mothers should only use this drug when it is clearly necessary and prescribed by a physician.

    Approval Date: 2000-07-01
    Date Created: 2000-09-28 12:00:00
    Company Name: B Braun Medical
    Back to Listings

    Upcoming Events

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    • China-360x240

      U.S. Tops List of Trial Startups With China Making Progress in Phase 1

    • Phoneapp-360x240

      Device Apps Present Unique Risks in Trials

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing